← ANALYST RATINGS · TIPRANKS
First Tracks Biotherapeutics Inc (TRAX): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $77.50, the highest $100, the lowest $60.00. The average is +124.9% from the last price of $34.46.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $35.00 → $36.00+2.9% | Hold | +4.5% | Reiterated | 17.10.26on TipRanks 12:05 | — | |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $70.00 → $90.00+28.6% | Buy | +161.2% | Reiterated | 16.10.26on TipRanks 08:35 | −3.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $32.00 → $35.00+9.4% | Hold | +1.6% | Reiterated | 13.10.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $33.00 → $35.00+6.1% | Hold | +1.6% | Reiterated | 13.10.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $33.00 → $36.00+9.1% | Hold | +4.5% | Reiterated | 13.10.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $32.00 → $34.00+6.2% | Hold | −1.3% | Reiterated | 13.10.26on TipRanks 14:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $32.00 → $35.00+9.4% | Hold | +1.6% | Reiterated | 13.10.26on TipRanks 14:05 | — | |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $70.00 | Buy | +103.1% | Reiterated | 13.10.26on TipRanks 09:25 | −6.9%next day +8.8% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $65.00 → $70.00+7.7% | Buy | +103.1% | Reiterated | 13.10.26on TipRanks 08:41 | −6.9%next day +8.8% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $50.00 → $60.00+20.0% | Buy | +74.1% | Reiterated | 13.10.26on TipRanks 07:10 | −6.9%next day +8.8% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $65.00 | Buy | +88.6% | Reiterated | 13.10.26on TipRanks 04:50 | −6.9%next day +8.8% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | — | Buy | — | Reiterated | 12.10.26on TipRanks Oct 13 09:05 | +7.0%next day −6.9% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $100 | Buy | +190.2% | Reiterated | 12.10.26on TipRanks Oct 13 07:10 | +7.0%next day −6.9% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $62.00 → $70.00+12.9% | Buy | +103.1% | Reiterated | 12.10.26on TipRanks 17:45 | −6.9%next day +8.8% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $57.00 | Buy | +65.4% | Reiterated | 03.09.26on TipRanks 06:15 | −7.2%next day −4.4% · 5 days −13.1% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $95.00 | Buy | +175.7% | Reiterated | 27.08.26on TipRanks 07:55 | +0.6%next day −6.2% · 5 days −5.3% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $65.00 | Buy | +88.6% | Assigned | 13.08.26on TipRanks 07:55 | −5.2%next day +0.2% · 5 days −2.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering First Tracks Biotherapeutics Inc
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $68.70 at a price of $35.44 (+93.8%); now: $74.20 at $34.46 (+115.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 5 | 4 | 7 | 18 |
| Buy | 0 | 0 | 7 | 9 | 10 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About First Tracks Biotherapeutics Inc
- CEO: Daniel R. Faga
- Employees: 104
- 10770 Wateridge Circle, San Diego, CA, 92121, US
- www.firsttracksbio.com
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Data from the stock’s TipRanks forecast page, read 9 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗